Author

T. Naert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:genetic perturbation / CRISPR· 2 Organism:Xenopus· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

C. Vanhove· 2 shared D. Creytens· 2 shared D. Tulkens· 2 shared K. Vleminckx· 2 shared S. Demuynck· 2 shared B. Alman· 1 shared D. Deforce· 1 shared D. Dimitrakopoulou· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Vanhove

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR-SID: identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping

T. Naert, D. Tulkens, T. Van Nieuwenhuysen, J. Przybyl, S. Demuynck, M. van de Rijn, M. Al Jazrawe, B. Alman, P. J. Coucke, K. De Leeneer, C. Vanhove, S. N. Savvides, D. Creytens, K. Vleminckx

This paper introduces CRISPR-SID, a method to identify tumor dependencies in Xenopus models, revealing EZH2 as a druggable target for desmoid tumors.

bioRxiv · Sep 1, 2021Cancer Biology

RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma

T. Naert, D. Dimitrakopoulou, D. Tulkens, S. Demuynck, R. Noelanders, L. Eeckhout, G. Van Isterdael, D. Deforce, C. Vanhove, J. Van Dorpe, D. Creytens, K. Vleminckx

This study uses CRISPR/Cas9 in Xenopus tropicalis to show that RBL1/p107 compensates for RB1 loss in driving specific cancers like SC-PaNEC and retinoblastoma.

bioRxiv · Jan 23, 2019Cancer Biology